Coordination of COVID-19 platform trials in Europe

J 2024

Coordination of COVID-19 platform trials in Europe

DEMOTES, Jacques; Victoria Charlotte SIMENSEN; Keiko UEDA; Sareema JAVAID; Paula GARCIA et. al.

Základní údaje

Originální název

Coordination of COVID-19 platform trials in Europe

Autoři

DEMOTES, Jacques; Victoria Charlotte SIMENSEN; Keiko UEDA; Sareema JAVAID; Paula GARCIA; Burc AYDIN a John-Arne ROTTINGEN

Vydání

Clinical Trials and Meta-analysis/Clinical Trials Journal, LONDON, Elsevier, 2024, 0927-5401

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

COVID ECRIN

Kód RIV

RIV/00216224:90034/24:00138394

Organizační jednotka

CZECRIN

DOI

http://dx.doi.org/10.1186/s13063-024-08126-5

UT WoS

001207766800001

Klíčová slova česky

Adaptive platform trial; COVID-19; Coordination mechanism

Klíčová slova anglicky

Adaptive platform trial; COVID-19; Coordination mechanism

Štítky

CZECRIN, ECRIN, Excelence Science, RIV, user, článek v časopise

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 2. 2025 10:06, Bc. Hana Vladíková, BBA

Anotace

V originále

To ensure optimal coordination of the EU-funded COVID-19 platform trials, a double coordination mechanism was established. It included the Trial Coordination Board (TCB) to promote the dialogue between investigators and relevant public health stakeholders and the Joint Access Advisory Mechanism (JAAM) to streamline access of new intervention arms to the platform trials. Both the TCB and the JAAM emerged as efficient instruments to promote cooperation and optimise the use of resources within EU-funded adaptive platform trials. In addition, an adaptive platform trial toolbox was developed to collect information and literature on challenges and solutions identified to date. The recently funded 'Coordination MEchanism for Cohorts and Trials' (CoMeCT) project will endeavour to make this model sustainable, with a further expansion to other emerging infectious diseases, as part of the governance of the current and future platform trials for pandemic preparedness. This example could serve as a model for platform trial coordination in other disease areas.

Návaznosti

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

DEMOTES, Jacques; Victoria Charlotte SIMENSEN; Keiko UEDA; Sareema JAVAID; Paula GARCIA; Burc AYDIN a John-Arne ROTTINGEN. Coordination of COVID-19 platform trials in Europe. Clinical Trials and Meta-analysis/Clinical Trials Journal. LONDON: Elsevier, 2024, roč. 25, č. 1, s. 1-5. ISSN 0927-5401. Dostupné z: https://dx.doi.org/10.1186/s13063-024-08126-5.

@article{2466300,
   author = {Demotes, Jacques and Simensen, Victoria Charlotte and Ueda, Keiko and Javaid, Sareema and Garcia, Paula and Aydin, Burc and Rottingen, JohnandArne},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13063-024-08126-5},
   keywords = {Adaptive platform trial; COVID-19; Coordination mechanism},
   language = {eng},
   issn = {0927-5401},
   journal = {Clinical Trials and Meta-analysis/Clinical Trials Journal},
   title = {Coordination of COVID-19 platform trials in Europe},
   url = {https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-024-08126-5},
   volume = {25},
   year = {2024}
}

TY  - JOUR
ID  - 2466300
AU  - Demotes, Jacques - Simensen, Victoria Charlotte - Ueda, Keiko - Javaid, Sareema - Garcia, Paula - Aydin, Burc - Rottingen, John-Arne
PY  - 2024
TI  - Coordination of COVID-19 platform trials in Europe
JF  - Clinical Trials and Meta-analysis/Clinical Trials Journal
VL  - 25
IS  - 1
SP  - 1-5
EP  - 1-5
PB  - Elsevier
SN  - 09275401
KW  - Adaptive platform trial
KW  - COVID-19
KW  - Coordination mechanism
UR  - https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-024-08126-5
N2  - To ensure optimal coordination of the EU-funded COVID-19 platform trials, a double coordination mechanism was established. It included the Trial Coordination Board (TCB) to promote the dialogue between investigators and relevant public health stakeholders and the Joint Access Advisory Mechanism (JAAM) to streamline access of new intervention arms to the platform trials. Both the TCB and the JAAM emerged as efficient instruments to promote cooperation and optimise the use of resources within EU-funded adaptive platform trials. In addition, an adaptive platform trial toolbox was developed to collect information and literature on challenges and solutions identified to date. The recently funded 'Coordination MEchanism for Cohorts and Trials' (CoMeCT) project will endeavour to make this model sustainable, with a further expansion to other emerging infectious diseases, as part of the governance of the current and future platform trials for pandemic preparedness. This example could serve as a model for platform trial coordination in other disease areas.
ER  -

DEMOTES, Jacques; Victoria Charlotte SIMENSEN; Keiko UEDA; Sareema JAVAID; Paula GARCIA; Burc AYDIN a John-Arne ROTTINGEN. Coordination of COVID-19 platform trials in Europe. \textit{Clinical Trials and Meta-analysis/Clinical Trials Journal}. LONDON: Elsevier, 2024, roč.~25, č.~1, s.~1-5. ISSN~0927-5401. Dostupné z: https://dx.doi.org/10.1186/s13063-024-08126-5.

Přehled o publikaci